# A Safety Study of ABI-007 for In-Stent Restenosis

> **NCT00093223** · PHASE2 · COMPLETED · sponsor: **Celgene** · enrollment: 76 (actual)

## Conditions studied

- Angina Pectoris
- Coronary Artery Disease

## Interventions

- **DRUG:** Paclitaxel Nanoparticle Albumin Bound
- **DRUG:** Paclitaxel Nanoparticle Albumin Bound
- **DRUG:** Paclitaxel Nanoparticle Albumin Bound

## Key facts

- **NCT ID:** NCT00093223
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-09-01
- **Primary completion:** 2007-12-01
- **Final completion:** 2007-12-01
- **Target enrollment:** 76 (ACTUAL)
- **Last updated:** 2019-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00093223

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00093223, "A Safety Study of ABI-007 for In-Stent Restenosis". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00093223. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*